Aniruddha Vaidya
Department of Community Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha, Maharashtra, IndiaPublications
-
Review Article
Role of Antifibrotic Therapy in Pulmonary Fibrosis Due to COVID-19
Author(s): Guddi Laishram* and Aniruddha Vaidya
Background: It has been more than year of beginning of COVID-19 outbreak, the most serious complication of COVID infection is excessive increase in inflammatory mediators also known as cytokine storm which leads to formation of pneumonia in some patients. After resolution of pneumonia some amount of fibrosis develops which leads to decrease in quality of life and increased mortality. Nevertheless, in elderly patients a small % of fibrosis can be fatal. Therefore, as corona virus has affected several millions of people even though pulmonary fibrosis being a rare complication can cause huge no. of cases of pulmonary fibrosis, Several randomized control trials has been carried out till now for treatment of fibrosis, Perfenidone and nintedanib are approved as a treatment modality of idiopathic pulmonary fibrosis, it has been also useful in .. Read More»